Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease

International Journal of Angiology

Volumn 24, Issue 4, 2014, Pages 278-282

  Hikita, Hiroyuki ^a   Shigeta, Takatoshi ^a   Kimura, Shigeki ^a   Takahashi, Atsushi ^a   Isobe, Mitsuaki ^b  

^a YOKOSUKA KYOSAI HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

cardiac biomarkers; cardiac catheterization; cardiovascular disease; claudication; coronary artery; critical limb ischemia; peripheral artery disease

Indexed keywords

EID: 84948085421     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0035-1555133     Document Type: Article

References (29)

1. Criqui M. H., Langer R. D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med: 1992; 326 6 381 386
2. Norgren L., Hiatt W. R., Dormandy J. A., Nehler M. R., Harris K. A., Fowkes F. G.; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg: 2007; 45 (Suppl S): S5 S67
3. Gensini G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol: 1983; 51 3 606
4. Eapen D. J., Manocha P., Ghasemzedah N., et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc: 2014; 3 5 e001118
5. Saunders J. T., Nambi V., de Lemos J. A., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation: 2011; 123 13 1367 1376
6. Linnemann B., Sutter T., Herrmann E., et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. J Am Coll Cardiol: 2014; 63 15 1529 1538
7. Gaubatz J. W., Heideman C., Gotto A. M. Jr, Morrisett J. D., Dahlen G. H. Human plasma lipoprotein [a]. Structural properties. J Biol Chem: 1983; 258 7 4582 4589
8. McLean J. W., Tomlinson J. E., Kuang W. J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature: 1987; 330 6144 132 137
9. Sorensen K. E., Celermajer D. S., Georgakopoulos D., Hatcher G., Betteridge D. J., Deanfield J. E. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest: 1994; 93 1 50 55
10. Nielsen L. B., Nordestgaard B. G., Stender S., Niendorf A., Kjeldsen K. Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol: 1995; 15 9 1492 1502
11. Nielsen L. B., Stender S., Jauhiainen M., Nordestgaard B. G. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest: 1996; 98 2 563 571
12. Nielsen L. B., Stender S., Kjeldsen K., Nordestgaard B. G. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res: 1996; 78 4 615 626
13. Nielsen L. B., Gronholdt M. L., Schroeder T. V., Stender S., Nordestgaard B. G. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol: 1997; 17 5 905 911
14. Boffa M. B., Marcovina S. M., Koschinsky M. L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem: 2004; 37 5 333 343
15. Maher V. MG, Brown B. G., Marcovina S. M., Hillger L. A., Zhao X. Q., Albers J. J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA: 1995; 274 22 1771 1774
16. Kamstrup P. R., Benn M., Tybjaerg-Hansen A., Nordestgaard B. G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation: 2008; 117 2 176 184
17. Kamstrup P. R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA: 2009; 301 22 2331 2339
18. Lavie C. J., Milani R. V., Mehra M. R., Ventura H. O. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol: 2009; 54 7 585 594
19. Weitz D., Weintraub H., Fisher E., Schwartzbard A. Z. Fish oil for the treatment of cardiovascular disease. Cardiol Rev: 2010; 18 5 258 263
20. Iso H., Kobayashi M., Ishihara J., et al. JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation: 2006; 113 2 195 202
21. Yokoyama M., Origasa H., Matsuzaki M., et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet: 2007; 369 9567 1090 1098
22. Kondo T., Ogawa K., Satake T., et al. Plasma-free eicosapentaenoic acid/arachidonic acid ratio: a possible new coronary risk factor. Clin Cardiol: 1986; 9 9 413 416
23. Kashiyama T., Ueda Y., Nemoto T., et al. Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J: 2011; 75 10 2432 2438
24. Domei T., Yokoi H., Kuramitsu S., et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J: 2012; 76 2 423 429
25. Rutherford R. B., Baker J. D., Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg: 1997; 26 3 517 538
26. Austen W. G., Edwards J. E., Frye R. L., et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association. Circulation: 1975; 51 (4, Suppl): 5 40
27. Langsted A., Kamstrup P. R., Nordestgaard B. G. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis: 2014; 234 1 95 101
28. Cheng S. W., Ting A. C. Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg: 2001; 22 2 124 129
29. Ninomiya T., Nagata M., Hata J., et al. Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis: 2013; 231 2 261 267